Atai Life Sciences reports Q4 2023 net loss $18.3M, cash $154.2M; BPL-003 Phase 2a shows 45% remission at 3 months

ATAI Life Sciences N.V.

Net loss for Q4 2023 was $18.3M vs $45.0M in Q4 2022; full-year net loss $40.2M vs $152.4M.
Cash and short-term investments $154.2M as of Dec 31, 2023, down from $273.1M a year ago.
R&D expenses decreased to $62.2M for FY 2023 from $74.3M; G&A expenses decreased to $63.6M from $70.4M.
Strategic investment in Beckley Psytech (Jan 2024) added BPL-003 and ELE-101; Phase 2b BPL-003 results expected 2H 2024.
VLS-01 Phase 1b dosing initiated; COMP360 Phase 3 top-line data expected Q4 2024 and mid-2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

ATAI Life Sciences N.V. reported financial results for Q4 and FY 2023.

Period: Q4 and FY 2023
Result: reported results

Exact text from the filing

atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001140361-24-015908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.